TelyRx Holdings Inc. saw a notable increase in its stock price, closing up 3.56% in yesterday's session.
In a positive turn for investors, TelyRx Holdings Inc. (TELY.TO) experienced a 3.56% rise in its stock price yesterday, closing at CA$2.33. This upward movement reflects growing confidence in the company's future prospects as it continues to expand its digital pharmacy platform.
Investor takeaway: The recent gains in TelyRx's stock highlight investor optimism, particularly in light of the company's significant revenue growth reported in recent financial results.
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$59.83M
52W high
$4.25
52W low
$2.00
1W change
+8.37%
Analyst Price Targets
Based on analyst covering TELY · as of Sep 17, 2026
Wall Street analysts forecast TELY stock price to rise 157.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+157.5% Upside
Current Price
C$2.33
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
68.4%
Annualized
90-Day Vol
90.3%
Annualized
Trend (90d)
-12.4%
Annualized drift
90d Mean
C$2.23
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.30 | C$1.81 – C$2.91 |
| 60 trading days | C$2.26 | C$1.62 – C$3.16 |
| 90 trading days | C$2.23 | C$1.48 – C$3.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
3.56% Increase in Stock Price
TelyRx's stock price increased from CA$2.25 to CA$2.33, marking a significant gain in investor confidence.
Bull case
TelyRx's revenue growth is impressive, with a reported increase to CA$42.9 million for the year ended December 31, 2025. This suggests strong demand for its services, which could attract more investors and push the stock price even higher.
Bear case
Despite the recent gains, TelyRx still faces challenges. The company continues to report net losses, raising concerns about its long-term profitability and sustainability in a competitive market.
Advertisement
Understanding TelyRx's Growth
TelyRx's recent financial results showcased a remarkable increase in revenue, rising to CA$42.9 million for the year ended December 31, 2025. This growth is attributed to the company’s expanding digital pharmacy platform, which connects patients with licensed providers across the U.S. The increase in prescriptions filled, from 53,390 in Q4 2024 to 177,713 in Q4 2025, signals a growing customer base and demand for their services.
Market Reaction and Future Outlook
The stock's 3.56% increase yesterday reflects a positive market reaction to TelyRx's performance. However, investors should remain cautious, as the company continues to report net losses. The balance between growth and profitability will be crucial for sustaining investor interest. For more insights into TelyRx's performance, check out our detailed analysis on TelyRx Holdings Inc. stock.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
